We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Clinical Updates

Malignancy Risk Patterns in Solid Organ Transplant Recipients with a History of Pretransplant Cancer

MedXY Editorial Team•Mar 15, 2026•Clinical Updates
immunosuppressiononcologytransplantationがんサバイバーシップ

Highlights

  • Solid organ transplant (SOT) recipients with a pretransplant cancer history have a significantly increased risk of developing the same type of cancer posttransplant.
  • The highest risk association was observed for melanoma, with an incidence rate ratio (IRR) of 10.4.
  • Specific cross-cancer associations exist, such as pretransplant kidney cancer increasing the risk of posttransplant thyroid cancer.
  • Risk levels for certain cancers (liver, kidney, lung) in SOT recipients were lower than standardized incidence ratios (SIRs) seen in cancer survivors in the general population, suggesting complex interactions between organ disease and immunosuppression.

Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Pembrolizumab Plus Chemotherapy for Cervical Cancer: Five-Year Exploratory Analysis from the KEYNOTE-826 Randomized Clinical TrialFive-year data from KEYNOTE-826 confirm pembrolizumab combined with chemotherapy as a durable, first-line treatment improving survival in persistent, recurrent, or metastatic cervical cancer without new safety concerns.Sep 15, 2026HPV-Associated Anal Dysplasia in Solid Organ Transplant Recipients: Unraveling Transplant-Specific Mucosal Immune DysfunctionSolid organ transplant recipients have increased risk of HPV-driven anal dysplasia and cancer due to unique immune alterations from immunosuppression. This article explores the transplant-specific immune dysfunction underlying persistent HPSep 5, 2026Reevaluating Calcineurin Inhibitor Use in Identical Twin Kidney Transplants: Are We Overmedicating?Despite identical immunogenetic makeup, half of kidney transplant recipients from identical twins remain on calcineurin inhibitors, with no demonstrable benefit in rejection reduction or graft survival over 25 years, calling for critical reSep 4, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Cancer Biologics Utilization After Biosimilar Entry and Financial Implications For Payers and Patients
This study examines the impact of biosimilar introduction on cancer biologics, highlighting reduced costs and market share for originator biologics, benefiting both payers and patients.
Aug 29, 2026
Belatacept and Sirolimus Show Promise as Safer Immunosuppression in Islet Transplantation for Type 1 DiabetesA multi-centre phase 2 study demonstrates that belatacept combined with sirolimus achieves superior islet transplant outcomes with better renal preservation compared to conventional tacrolimus-based therapy in type 1 diabetes patients.Aug 18, 2026
Menopause Management in Patients with Cancer: A Symptom‑Based, Risk‑Stratified FrameworkPractical, symptom‑focused recommendations for managing menopause in people with cancer—balancing symptom relief with oncologic safety using nonhormonal first-line strategies, selective use of local estrogen, and shared decision making forAug 12, 2026